Local striatal infusion of MPP+ does not result in increased hydroxylation after systemic administration of 4-hydroxybenzoate

Free Radical Biology and Medicine

Volumn 27, Issue 9-10, 1999, Pages 997-1007

  Ste Marie, Line ^a,b   Vachon, Luc ^a   Bémeur, Chantal ^a,b   Lambert, Jean ^b   Montgomery, Jane ^a,b  

^a NOTRE DAME HOSPITAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

1 deprenyl; 4 Hydroxybenzoate; Free radicals; MDL 72,974A; MPP+; Parkinson's disease

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 3,4 DIHYDROXYPHENYLACETIC ACID; 4 HYDROXYBENZOIC ACID; AMINE OXIDASE (FLAVIN CONTAINING) ISOENZYME B; DOPAMINE; HOMOVANILLIC ACID; HYDROXYL RADICAL; MOFEGILINE; MONOAMINE OXIDASE B INHIBITOR; SCAVENGER; SELEGILINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN INJURY; CONTROLLED STUDY; CORPUS STRIATUM; DRUG HYDROXYLATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAPERITONEAL DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; PRIORITY JOURNAL; RAT;

1-METHYL-4-PHENYLPYRIDINIUM; ALLYL COMPOUNDS; ANIMALS; ANTIOXIDANTS; BUTYLAMINES; CORPUS STRIATUM; DOPAMINE; FREE RADICAL SCAVENGERS; HYDROXYBENZOIC ACIDS; HYDROXYL RADICAL; HYDROXYLATION; INJECTIONS, INTRAPERITONEAL; MALE; MICRODIALYSIS; MONOAMINE OXIDASE INHIBITORS; NEUROTOXINS; PARABENS; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; SELEGILINE;

EID: 0033231195     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5849(99)00170-7     Document Type: Article

References (60)

1. [1] Dexter, D. T.; Carter, C. J.; Wells, F. R.; Javoy-Agid, F.; Agid, Y.; Lees, A.; Jenner, P.; Marsden, C. D. Basai lipid peroxidation in substantia nigra is increased in Parkinson's disease. J. Neurochem. 52:1830-1836; 1989.
2. [2] Yoritaka, A.; Hattori, N.; Uchida, K.; Tanaka, M.; Stadtman, E.R.; Mizuno, Y. Immunohistochemical detection of 4-hydroxynonenal protein adducts in Parkinson's disease. Proc. Nat. Acad. Sci. USA 93:2696-2701; 1996.
3. [3] Perry, T. L.; Godin, D. V.; Hansen, S. Parkinson's disease: a disorder due to nigral glutathione deficiency? Neurosci. Lett. 33:305-310; 1982.
4. [4] Riederer, P.; Sofie, E.; Rausch, W. D.; Schmidt, B.; Reynolds, G. P.; Jellinger, K.; Youdim, M. B. H. Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brain. J. Neurochem. 52:515-520; 1989.
5. [5] Sofic, E.; Lange, K. W.; Jellinger, K.; Riederer, P. Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci. Lett. 142:128-130; 1992.
6. [6] Church, W. H.; Ward, V. L. Uric acid is reduced in the substantia nigra in Parkinson's disease: effect on dopamine oxidation. Brain Res. Bull. 33:419-425; 1994.
7. [7] Marttila, R. J.; Lorentz, H.; Rinne, U. K. Oxygen toxicity protecting enzymes in Parkinson's disease. Increase of Superoxide dismutase-like activity in the substantia nigra and basal nucleus. J. Neurol. Sci. 86:321-331; 1988.
8. [8] Saggu, H.; Cooksey, J.; Dexter, D.; Wells, F. R.; Lees, A.; Jenner, P.; Marsden, C. D. A selective increase in particulate Superoxide dismutase activity in parkinsonian substantia nigra. J. Neurochem. 53:692-697; 1989.
9. [9] Dexter, D. T.; Wells, F. R.; Agid, F.; Agid, Y.; Lees, A. J.; Jenner, P.; Marsden, C. D. Increased nigral iron content in postmortem Parkinsonian brain. Lancet 2:1219-1220; 1987.
10. [10] Dexter, D. T.; Wells, F. R.; Lees, A.; Agid, F.; Agid, Y.; Jenner, P.; Marsden, C. D. Increased nigral iron content and alterations in other metal ions occurring in brain in Parkinson's disease. J. Neurochem. 52:1830-1836; 1989.
11. [11] Dexter, D. T.; Carayon, A.; Javoy-Agid, F. Alterations in the levels of iron, ferritin, and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain 114:1953-1975; 1991.
12. [12] Youdim, M. B. H.; Ben-Shachar, D.; Reiderer, P. Is Parkinson's disease a progressive siderosis of substantia nigra resulting in iron and melanin induced neurodegeneration? Acta Neurol. Scand. 26:47-54; 1989.
13. [13] Krige, D.; Carroll, M. T.; Cooper, J. M.; Marsden, C. D.; Schapira, A. H. V. Platelet mitochondrial function in Parkinson's disease. Ann. Neurol. 32:782-788; 1992.
14. [14] Di Monte, D. A.; Sandy, M. S.; Jewell, S. A.; Adornato, B.; Tanner, C. M.; Langsten, J. W. Oxidative phosphorylation by intact muscle mitochondria in Parkinson's disease. Neurodegeneration 2:275-281; 1993.
15. [15] dela Torre, R.; Casado, A.; Lopez-Fernandez, E.; Carrascosa, D.; Casado, C.; Venarucci, D.; Venarucci, V. Human aging brain disorders: role of antioxidant enzymes. Neurochem. Res. 21:885-888; 1996.
16. [16] Parboosingh, J. S.; Rousseau, M.; Rogan, F.; Amit, Z.; Chertkow, H.; Johnson, W. G.; Manganaro, F.; Schipper, H. N.; Curran, T. J.; Stoessl, J.; Rouleau, G. Absence of mutations in Superoxide dismutase and catalase genes in patients with Parkinson's disease. Arch. Neurol. 52:1160-1163; 1995.
17. [17] Langsten, J. W.; Ballard, P.; Tetrad, J. W.; Irwin, I. Chronic parkinsonism in humans due to a product of meperidine-analog synthesis. Science 219:979-980; 1983.
18. [18] Markey, S. P.; Johannessen, J. N.; Chiueh, C. C.; Burns, R. S.; Herkenham, M. A. Intraneuronal generation of a pyridinium metabolite may cause drug-induced parkinsonism. Nature 311:464-467; 1984.
19. [19] Chiba, K; Trevor, A.; Castagnoli, N. Metabolism of the neurotoxic tertiary amine, MPTP, by brain monoamine oxidase. Biochem. Biophys. Res. Commun. 120:574-578; 1984.
20. [20] Chiba, K; Peterson, L. A.; Castagnoli, K. P.; Trevor, A. J.; Castagnoli, N. Studies on the molecular bioactivation of the selective nigrostriatal toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyndme. Drug Metab. Dispos. 13:342-347; 1985.
21. [21] Javitch, J. A.; D'Amato, R. J.; Strittmatter, S. M.; Snyder, S. H. Parkinsonism-inducing neurotoxin, N-methyl-4-phenyl-1,2,3,6-tetrahydropyridine: uptake of the metabolite N-methyl-4-phenylpyridine by dopamine neurons explains selective neurotoxicity. Proc. Nat. Acad. Sci. USA 82:2173-2177; 1985.
22. +. Biochem. Biophys. Res. Commun. 134:743-748; 1986.
23. [23] Nicklas, W. J.; Vyas, I.; Heikkila, R. E. Inhibition of NADH-linked oxidation in brain mitochondria by 1-methyl-4-phenylpyridine, a metabolite of the neurotoxin, 1-methyl-4-phenyl-1,2,3,6-tetrahydropyndine. Life Sci. 36:2503-2508; 1985.
24. [24] McCord, J. The Superoxide free radical: its biochemistry and pathophysiology. Surgery 94:412-414; 1983.
25. [25] Chiueh, C. C.; Murphy, D. L.; Miyake, H.; Lang, K.; Tulsi, P. K.; Huang, S.-J. Hydroxyl free radical (*OH) formation reflected by salicylate hydroxylation and neuromelanin. In vivo markers for oxidant injury of nigral neurons. Ann. N.Y. Acad. Sci. 679:370-374; 1993.
26. [26] Chiueh, C. C.; Huang, S.-J.; Murphy, D. L. Enhanced hydroxyl radical generation by 2′-methyl analog of MPTP: suppression by clorgyline and 1-deprenyl. Synapse 11:346-348; 1992.
27. +. Free Radic. Biol. Med. 13:581-583; 1992.
28. +. J. Neural Transm. Gen. Sect. 89:139-145; 1992.
29. + in vivo. Eur. J. Pharmacol. 243: 241-247; 1993.
30. [30] Floyd R.; Watson, J.; Wong, P. Sensitive assay of hydroxyl free radical formation utilizing HPLC with electrochemical detection of phenol and salicylate hydroxylation products. J. Biochem. Biophys. Meth. 10:221-235; 1984.
31. [31] Ste-Marie, L.; Boismenu, D.; Vachon, L.; Montgomery, J. Evaluation of sodium 4-hydroxybenzoate as an in vivo hydroxyl radical trap using gas chromatography-mass spectrometry and high performance liquid chromatography with electrochemical detection. Anal. Biochem. 241:67-74; 1996.
32. [32] Montgomery, J. A.; Ste-Marie, L.; Boismenu, D.; Vachon, L. Hydroxylation of aromatic compounds as indices of hydroxyl radical production: a cautionary note revisited. Free Radic. Biol. Med. 19:927-933; 1995.
33. [33] Palfreyman, M. G.; McDonald, I. A.; Zreika, M.; Cremer, G.; Haegele, K. D.; Bey, P. MDL 72,974A: a selective MAO-B inhibitor with potential for treatment of Parkinson's disease. J. Neural Transm. 40(Suppl.):101-111; 1993.
34. [34] Palfreyman, M. G., McDonald, I. A., Bey, P., Schechter, P. J.; Sjoerdsma, A. Design and early clinical evaluation of selective inhibitors of monoamine oxidase. Prog. Neuro-Psychopharmacol. Biol. Psychiat. 12:967-987; 1988.
35. [35] Paxinos, G.: Watson, C. The rat brain in stereotaxic co-ordinates, 2nd ed. Toronto: Academic Press; 1986.
36. [36] Cumming, P.; Brown, E.; Damsma, G.; Fibiger, H. Formation and clearance of interstitial metabolites of dopamine and serotonin in the rat striatum: an in vivo microdialysis study. J. Neurochem. 59:1905-1914; 1992.
37. [37] Zreika, M.; Fozard, J. R.; Dudley, M. W.; Bey, P.; McDonald, I. A.; Palfreyman, M. G. MDL 72,974: a potent and selective enzyme-activated irreversible inhibitor of monoamine oxidase type B with potential for use in Parkinson's disease. J. Neural Transm. Park. Dis. Dement. Sect. 1:243-254; 1989.
38. [38] Des Rosiers, C.; Rivest, M.-J.; Jetté, M.; Carrobé-Cohen, A.; Kumar, A. Gas chromatographic-mass spectrometric assay of tissue malondialdehyde, 4-hydroxynonenal and other aldehydes after their reduction to stable alcohols. Anal. Biochem. 208:161-170; 1993.
39. [39] Cohen, G. The Fenton Reaction. In: Greenwald, R. A., ed., CRC handbook of methods for oxygen radical research. Boca Raton: CRC Press; 1985:55-63.
40. +-like neurotoxicity of a pyridinium metabolite derived from haloperidol: in vivo microdialysis and in vitro mitochondrial studies. J. Pharmacol. Exp. Ther. 268:380-387; 1994.
41. [41] Giovanni, A.; Sonsalla, P. K.; Heikkila, R. E. Studies on species sensitivity to the dopaminergic neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. Part 2: Central administration of 1-methyl-4-phenylpyridinium. J. Pharmacol. Exp. Ther. 270: 1008-1014; 1994.
42. [42] Althaus, J. S.; Andrus, P. K.; Williams, C. M.; VonVoigtlander, P. F.; Gazers, A. R.; Hall, E. D. The use of salicylate hydroxylation to detect hydroxyl radical generation in ischemic and traumatic brain injury. Mol. Chem. Neuropathol. 20:147-162; 1993.
43. +-induced cell injury in the striatum of rats. Br. J. Pharmacol. 111:837-842; 1994.
44. + toxicity on striatal dopaminergic terminals. J. Neurochem. 68:732-738; 1997.
45. [45] Finnegan, K. T. Neurotoxins and monoamine oxidase inhibition: new aspects. Mov. Disord. 8:514-519; 1993.
46. [46] Friedman, L. K.; Mytilineou, C. Neurochemical and toxic effects of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine and 1-methyl-4-phenylpyridine to rat serotonin neurons in dissociated cell cultures. J. Pharmacol. Exp. Ther. 253:892-898; 1990.
47. [47] Youngster, S.; McKeown, K. A.; Jin, Y.-Z.; Ramsay, R. R.; Heikkila, R.; Singer, T. Oxidation of analogues of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine by monoamine oxidases A and B and the inhibition of monoamine oxidases by the oxidation products. J. Neurochem. 53:1837-1842; 1989.
48. [48] Maruyama, W.; Naoi, M. Inhibition of tyrosine hydroxylase by a dopamine neurotoxin, 1-methyl-4-phenylpyridinium ion: depletion of allostery of the biopterin cofactor. Life Sci. 55:207-212; 1994.
49. [49] Werdinius, B. Effect of probenecid on the level of homovanillic acid in the corpus striatum. J. Pharm. Pharmacol. 18:546-547; 1966.
50. [50] Westerink, B.; Kikkert, R. Effect of various centrally acting drugs on the efflux of dopamine metabolites from the rat brain. J. Neurochem. 46:1145-1152; 1986.
51. [51] Moleman, P.; Bruinvels, J.; Van Valkenburg, C. Haloperidol inhibits the disappearance of acidic metabolites from the rat striatum. J. Pharm. Pharmacol. 30:583-585; 1978.
52. [52] Subramanyam, B.; Rollema, H.; Woolf, T.; Castagnoli, N. Jr. Identification of a potentially neurotoxic pyridinium metabolite of haloperidol in rats. Biochem. Biophys. Res. Commun. 166:238-244; 1990.
53. +-induced hydroxyl radical formation and nigrostriatal MPTP toxicity by inhibiting nitric oxide synthase. Neuroreport 5:2598-2600; 1994.
54. [54] Boismenu, D.; Mamer, O.; Ste-Marie, L.; Vachon, L.; Montgomery, J. In vivo hydroxylation of the neurotoxin, 1-methyl-4-phenylpyridinium, and the effect of monoamine oxidase inhibitors: electrospray-MS analysis of intra-striatal microdialysates. J. Mass Spectrom. 31:1101-1108; 1996.
55. [55] Chiueh, C. C.; Huang, S.-J.; Murphy, D. L. Suppression of hydroxyl radical formation by MAO inhibitors: a novel possible neuroprotective mechanism in dopamine neurotoxicity. J. Neural Transm. 41(Suppl.):189-196; 1994.
56. + toxicity by 1-deprenyl (selegiline). Ann. N.Y. Acad. Sci. 738:214-221; 1994.
57. + dopaminergic toxicity. J. Neural Transm. Gen. Sect. 100:53-61; 1995.
58. [58] Thomas, C.; Huber, E.; Ohlweiler, D. Hydroxyl and peroxyl radical trapping by the monoamine oxidase-B inhibitors 1-deprenyl and MDL 72,974A: implications for protection of biological substrates. Free Radic. Biol. Med. 22:733-737; 1997.
59. [59] Thiffault, C.; Quirion, R.; Poirier, J. Effect of the MAO-B inhibitor, MDL72974, on superoxide dismutase activity and lipid peroxidation levels in the mouse brain. Synapse 28:208-211; 1998.
60. [60] Gessner, W.; Brossi, A.; Shen, R.-S.; Abell, C. W. Synthesis and dihydropteridine reductase inhibitory effects of potential metabolites of the neurotoxin 1-methyl-4-phenyl-1,2,3,6,-tetrahydropyridine. J. Med. Chem. 28:311-317; 1985.